Industry & Business

Dublin startup scores €85 million funding for new approach to cancer therapy

 Breaking News
  • Irish Distillers to Invest €150 Million in Sites in Cork and Dublin Irish Distillers has announced investment of over €150 million in its sites in Cork and Dublin to meet demand for its products as the Irish whiskey renaissance continues apace. This is accelerated by the continued growth of the company’s flagship Jameson brand, which is now in double or triple-digit growth in more than 80 markets [...]...
  • CM Precision Components Opens New Purpose-built Factory in Downpatrick Downpatrick-based CM Precision Components Ltd has officially opened its new 16,000 sq ft manufacturing facility at Invest Northern Ireland’s Killough Road Industrial Estate. The advanced engineering firm has invested almost £1 million in the construction project, to expand its production capabilities and meet the growing demands of its customers. CM Precision Components produces precision machined components for [...]...
  • Arkphire Secures New Investment IT solutions and networking company, Arkphire, has announced that Bregal Milestone, a private capital firm, has completed an investment into the business. The investment by Bregal Milestone comes from their new €400 million pan-European fund dedicated to investing in high-growth European companies. Typical commitments from Bregal Milestone range from €20 million to €60 million. Arkphire provides [...]...
  • Government Investment in Research & Development Amounts to Over €750 Million in 2018 The latest figures on Government investment in research and development (R&D), published by the Department of Business, Enterprise and Innovation, show that over €750 million is estimated to have been invested in R&D in 2018. The data in The Research and Development Budget 2017-2018 publication is compiled from a comprehensive survey of thirty Government Departments [...]...
  • Smart Dublin in Partnership With Enterprise Ireland Award 21 New Innovation Contracts Approximately €700,000 is to be awarded to companies under Enterprise Ireland’s Small Business Innovation Research (SBIR) initiative which will enable them explore innovative solutions to address challenges faced by Local Authorities. 21 companies have been awarded Phase One funding to progress the feasibility of their solutions. Phase One funding will allow each recipient to carry [...]...

Dublin startup scores €85 million funding for new approach to cancer therapy

Dublin startup scores €85 million funding for new approach to cancer therapy
October 04
10:07 2016

Carrick Therapeutics, a Dublin-based startup specialising in a unique approach to cancer therapies, has launched having secured $95 (€85) million in funding.

Heavyweight investors have lined up to support the Irish company, with US firm ARCH Venture Partners, leading UK firm Woodford Investment Management and GV (Google Ventures) among those who have provided the capital. Lightstone Ventures, which is supported by Enterprise Ireland and the Irish Strategic Investment Fund, has also support Carrick.

The company will aim to build an innovative portfolio of first-in-class treatments that are advanced through understanding the mechanisms that cause cancer and resistance and tailored to an individual patient’s tumour.

Personalised cancer medicine, which is targeted at that specific patient’s cancer, is seen as a crucial next step in the fight against the disease. Cancer is so difficult to treat because of its unpredictability, but new scientific advances are developing more and more of an understanding about it affects each person.

Carrick Therapeutics has set out a clear vision to target the molecular pathways that drive the most aggressive and resistant forms of cancer in order to have a major impact on the lives of patients. With such large funding, the company will look to develop a portfolio of first-in-class treatments, rather than a single compound or biological mechanism.

Their CEO, Dr Elaine Sullivan, has previously worked as Vice President for Research and Development for pharma giants Eli Lilly and AstraZeneca.

She comments: “Our aim is to build Europe’s leading oncology company. There is a significant unmet need in cancer treatment, and targeting aggressive and resistant disease is an area where we can make a real difference to patients’ lives.”

Sullivan has indicated that Ireland was an ideal choice for their base of operations due to the opportunities for collaboration with clinicians and scientists, and because its skilled workforce makes it a great place for recruitment.

About Author

admin

admin

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4